Five-Year Impacts of Antithrombotic Therapy Based on 10-Year Clinical Outcomes of Cypher™ Stent Implantation.
Ken KuriharaShiho KawamotoAyaka KimuraAkifumi TanakaKento YabeHidetsugu NomotoYuki OsakaToru MiyazakiAsami SuzukiYuichi OnoKenichiro OtomoTetsuo SasanoPublished in: Cardiology and therapy (2022)
The incidence of ST after Cypher™ implantation in patients with DAPT at year 5 was significantly lower than that in SAPT. However, the risk of bleeding was higher with DAPT than with SAPT. Moreover, the risk of major bleeding was significantly higher in patients on anticoagulant therapy than in other patients. New options for the use of antithrombotic drugs after percutaneous coronary intervention warrant further studies on the optimal antithrombotic therapy for first-generation DES.
Keyphrases
- atrial fibrillation
- end stage renal disease
- ejection fraction
- percutaneous coronary intervention
- newly diagnosed
- chronic kidney disease
- prognostic factors
- antiplatelet therapy
- peritoneal dialysis
- stem cells
- risk factors
- acute myocardial infarction
- venous thromboembolism
- st segment elevation myocardial infarction
- mesenchymal stem cells
- bone marrow
- coronary artery bypass grafting
- cell therapy
- drug induced
- replacement therapy